drugset
drugset / Trial / NCT02410551

Pacritinib Before Transplant for Myeloproliferative Neoplasms (MPN)

NCT02410551 ↗

Phase 2 Terminated 4 enrolled M.D. Anderson Cancer Center CTI BioPharma · collab
NaSingle-groupOpen-labelTreatment

Summary

The goal of this clinical research study is to learn if giving pacritinib before standard of care drugs followed by an allogeneic stem cell transplant can help to control myeloproliferative neoplasms. The safety of this therapy will also be studied.

Timeline

Start
2015-06-15
Primary completion
2017-01-20
Completion
2017-01-20

Drugs

EvaluationDrugModalityDoseRoute
Subject Pacritinib Small molecule 200 mg Oral
Background Busulfan Small molecule 100 mg/m2 —
Background Fludarabine Small molecule — —

Indications

myeloproliferative neoplasm